Sarilumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL6 |
| Identifiers | |
| CAS Number |
1189541-98-7  |
| ATC code | none |
| ChemSpider | none |
| KEGG |
D10161 |
| Chemical data | |
| Formula | C6388H9918N1718O1998S44 |
| Molar mass | 144.13 kg/mol |
 (what is this?) (verify) | |
Sarilumab is a human monoclonal antibody against the interleukin-6 receptor.[1]
Regeneron and Sanofi are currently co-developing the drug for the treatment of rheumatoid arthritis (RA), for which it is in phase III trials.
Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial.[2]
Clinical trials
On May 15, 2013, both companies announced that 2 new trials were starting (COMPARE and ASCERTAIN) and the first patients had already been enrolled.[3]
In June 2015 a phase 3 trial (with methotrexate) for RA reported meeting its 3 coprimary endpoints.[4]
In Nov 2015 the SARIL-RA-TARGET trial reported good results (meeting both its coprimary end points).[5]
See also
- Anti-IL-6 anti-inflammatories
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Sarilumab" (PDF). American Medical Association. Needs subscription
- ↑ Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis. July 2011
- ↑ Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA). May 2013
- ↑ "Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.". Arthritis Rheumatol. 67 (6): 1424–37. 2015. doi:10.1002/art.39093.
- ↑ Sarilumab effective in broad range of RA patients: Study
This article is issued from Wikipedia - version of the Saturday, March 05, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.